United States: Amgen V. Sanofi – Impermissible Functional Claiming? - Oblon, McClelland, Maier & Neustadt, L.L.P

Mondaq

24 May 2023 0 shares 1 views

United States: Amgen V. Sanofi – Impermissible Functional Claiming? - Oblon, McClelland, Maier & Neustadt, L.L.P

Mondaq

Published 24 May 2023

On April 28 the Supreme Court heard oral arguments on Amgen's petition of the Federal Circuit's decision affirming the district court's decision on JMOL that Amgen's antibody claims...

Full Article

United States: It's Time To Change How Antibodies Are Claimed In Patent Strategy - Oblon, McClelland, Maier & Neustadt, L.L.P

The US Supreme Court announced its ruling May 18 in favor of Sanofi in its dispute with Amgen over the enablement requirement as it..

Mondaq 30 May 2023

United States: Supreme Court Affirms Federal Circuit Decision In Amgen v. Sanofi - Oblon, McClelland, Maier & Neustadt, L.L.P

The Court noted that that while the amino acid sequence of an antibody may be known, they have three-dimensional shapes and simply..

Mondaq 29 May 2023

United States: Amgen V. Sanofi – Impermissible Functional Claiming? - Oblon, McClelland, Maier & Neustadt, L.L.P

United States: Amgen V. Sanofi – Impermissible Functional Claiming? - Oblon, McClelland, Maier & Neustadt, L.L.P

You might like

Related news coverage

United States: It's Time To Change How Antibodies Are Claimed In Patent Strategy - Oblon, McClelland, Maier & Neustadt, L.L.P

United States: Supreme Court Affirms Federal Circuit Decision In Amgen v. Sanofi - Oblon, McClelland, Maier & Neustadt, L.L.P

Advertisement